30413-56-0

Usage

Uses

Used in Organic Synthesis:
4-Ethynyl-2-Methylpyridine is used as a building block for various organic synthesis reactions, providing a versatile platform for the creation of new compounds.
Used in Pharmaceutical Industry:
4-Ethynyl-2-Methylpyridine is used as a key intermediate in the development of pharmaceuticals, contributing to the synthesis of novel drug candidates.
Used in Agrochemical Industry:
4-Ethynyl-2-Methylpyridine is used as a component in the synthesis of agrochemicals, aiding in the development of new pesticides and other agricultural products.
Used in Materials Science:
4-Ethynyl-2-Methylpyridine is used in the field of materials science for the development of organic light-emitting diodes (OLEDs) and organic semiconductors, due to its unique chemical properties.
Used in Medicinal Chemistry and Drug Discovery:
4-Ethynyl-2-Methylpyridine is used as a compound of interest for its potential cytotoxic and antiproliferative activities, making it a candidate for further research and development in medicinal chemistry and drug discovery.

Upstream product

• 22282-99-1 4-bromo-2-methylpyridine 
• 1066-54-2 trimethylsilylacetylene 
• 761426-51-1 2-methyl-4-((trimethylsilyl)ethynyl)pyridine 

Downstream Products

• 1035267-67-4 4-[(3-bromo-4-fluorophenyl)ethynyI]-2-methyIpyridine 
• 1210835-37-2 C₂₁H₁₃Cl₂N₃O₂ 

Relevant academic research and scientific papers

ANTIBACTERIAL COMPOUNDS

The present invention relates to compounds of general formula (II),to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

Di-substituted pyridinyl aminohydantoins as potent and highly selective human β-secretase (BACE1) inhibitors

The identification of highly selective small molecule di-substituted pyridinyl aminohydantoins as β-secretase inhibitors is reported. The more potent and selective analogs demonstrate low nanomolar potency for the BACE1 enzyme as measured in a FRET assay, and exhibit comparable activity in a cell-based (ELISA) assay. In addition, these pyridine-aminohydantoins are highly selectivity (>500×) against the other structurally related aspartyl proteases BACE2, cathepsin D, pepsin and renin. Our design strategy followed a traditional SAR approach and was supported by molecular modeling studies based on the previously reported aminohydantoin 3a. We have taken advantage of the amino acid difference between the BACE1 and BACE2 at the S2′ pocket (BACE1 Pro70 changed to BACE2 Lys86) to build ligands with >500-fold selectivity against BACE2. The addition of large substituents on the targeted ligand at the vicinity of this aberration has generated a steric conflict between the ligand and these two proteins, thus impacting the ligand's affinity and selectivity. These ligands have also shown an exceptional selectivity against cathepsin D (>5000-fold) as well as the other aspartyl proteases mentioned. One of the more potent compounds (S)-39 displayed an IC50 value for BACE1 of 10 nM, and exhibited cellular activity with an EC50 value of 130 nM in the ELISA assay.

Inhibitors of HIV-1 reverse transcriptase

The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to Formulae I and II wherein Q, R1, R2, and R3 are defined as described herein.

NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES

This invention relates to novel compounds having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.